title: [Effect of hemodilution on retinal hemodynamics in retinal branch vein occlusion].
abstract: The aim of hemodilution therapy in branch retinal vein occlusion is to lower the hematocrit (HCT) and plasma viscosity and thus to ameliorate perfusion of the affected areas. In this study we compared the influence of hemodilution therapy on the retinal hemodynamics of affected areas with unaffected areas. Thirty patients with branch vein occlusion (duration of symptoms less than 14 days) aged 40-84 years (mean 63 +/- 11 years) were examined. All patients received iso- (HCT > or = 42%) or hypervolemic (HCT < 42%) hemodilution with hydroxyethyl-starch (MW 200,000/0.5 10%, HAES-steril) for 10 days. Retinal hemodynamics were quantified by means of video fluorescein angiography assessing arteriovenous passage time (AVP) of the affected and unaffected branches. Hemodilution resulted in a significant decrease in hematocrit, plasma viscosity and erythrocyte aggregation. The arteriovenous passage time of the affected area improved significantly (before therapy 4.91 +/- 2.2 s, after therapy 3.9 +/- 1.6 s). The unaffected branch showed no significant change in the arteriovenous passage time (1.85 +/- 0.7 s before and 1.79 +/- 0.7 s after therapy). The decrease in AVP in the affected branch indicates ameliorated perfusion in the affected branch area without changing the retinal hemodynamics in unaffected areas.
authors.affiliation: Augenklinik der RWTH Aachen.
authors.forename: A
authors.initials: A
authors.lastname: Remky
authors.forename: S
authors.initials: S
authors.lastname: Wolf
authors.forename: M
authors.initials: M
authors.lastname: Hamid
authors.forename: B
authors.initials: B
authors.lastname: Bertram
authors.forename: K
authors.initials: K
authors.lastname: Schulte
authors.forename: O
authors.initials: O
authors.lastname: Arend
authors.forename: M
authors.initials: M
authors.lastname: Reim
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001783:Blood Flow Velocity / Q000502:physiology; D005260:Female; D006400:Hematocrit; D006438:Hemodilution; D006439:Hemodynamics / Q000502:physiology*; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D012170:Retinal Vein Occlusion / Q000503:physiopathology / Q000628:therapy*
chemical_list: D006895:Hydroxyethyl Starch Derivatives